Effect of atorvastatin on hyperlipidemia and progression of carotid intima media thickness in steroid resistance nephrotic syndrome: A randomized controlled trial

ICMR0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Patient with LDL Cholesterol Between 130-300mg/dl on 2 occassions at least one week apart.
•2)Patient with stable dose of immunosuppressive medication (Prednisolone and Calcineurin inhibitors)for aperiod of 3 months.

•1) History of jaundice in last 6 months: AST/ALT levels more than twice normal of upper limit of the laboratory reference value.
•2) CPK levels more than 3 times normal.
•3) Children on lipid lowering agents such asHMG CoA reductase inhibitors in the past 3 months.
•4)Family History of premature CVD
•5)Patients with secondary nephrotic syndrome(SLE,IgAN,MPGN,MGN Alports disease)
•6)Patients on pulse corticosteroids or cyclophosphamide in last 6 months.
•7)Patients with stage 2 hypertension.
•8)GFR30ml/min/m2 or below
•9)Children residing beyond 200km from delhi.

发起方

ICMR